Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design

Mark Loeb, Hisham Dokainish, Antonio Dans, Lia M Palileo-Villanueva, Ambuj Roy, Kamilu Karaye, Jun Zhu, Yan Liang, Fastone Goma, Albertino Damasceno, Khalid F AlHabib, Gerald Yonga, Charles Mondo, Wael Almahmeed, Arif Al Mulla, Salim Yusuf, IVVE investigators, Mark Loeb, Hisham Dokainish, Antonio Dans, Lia M Palileo-Villanueva, Ambuj Roy, Kamilu Karaye, Jun Zhu, Yan Liang, Fastone Goma, Albertino Damasceno, Khalid F AlHabib, Gerald Yonga, Charles Mondo, Wael Almahmeed, Arif Al Mulla, Salim Yusuf, IVVE investigators

Abstract

Background: Influenza is associated with an increase in the risk of cardiac and other vascular events. Observational data and small randomized trials suggest that influenza vaccination may reduce such adverse vascular events.

Research design and methods: In a randomized controlled trial patients with heart failure are randomized to receive either inactivated influenza vaccine or placebo annually for 3 years. Patients aged ≥18 years with a clinical diagnosis of heart failure and NYHA functional class II, III and IV are eligible. Five thousand patients from 10 countries where influenza vaccination is not common (Asia, the Middle East, and Africa) have been enrolled. The primary outcome is a composite of the following: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalizations for heart failure using standardized criteria. Analyses will be based on comparing event rates between influenza vaccine and control groups and will include time to event, rate comparisons using Poisson methods, and logistic regression. The analysis will be conducted by intention to treat i.e. patients will be analyzed in the group in which they were assigned. Multivariable secondary analyses to assess whether variables such as age, sex, seasonality modify the benefits of vaccination are also planned for the primary outcome.

Conclusion: This is the largest randomized trial to test if influenza vaccine compared to control reduces adverse vascular events in high risk individuals.

Trial registration number: Clinicaltrials.govNCT02762851.

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Trial flow diagram.
Figure 2
Figure 2
Cumulative enrollment as of September 1, 2018.

References

    1. Causes of death. World Health Organization; Geneva: 2008.
    1. Statistics Canada . 2008. Morality, Summary List of Causes. [Released October 18, 2011]
    1. Tracking Heart Disease and Stroke in Canada. Released June 2009.
    1. Remme W.J., Torp-Pedersen C., Cleland J.G. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol. 2007;49(9):963–971.
    1. Gheorghiade M., Böhm M., Greene S.J., ASTRONAUT Investigators and Coordinators Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309:1125–1135.
    1. Massie B.M., Carson P.E., McMurray J.J. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–2467.
    1. Swedberg K., Komajda M., Bohm M. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
    1. Homma S., Thompson J.L., Pullicino P.M. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859–1869.
    1. Kinlay S., Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997;80:11I–16I.
    1. Chan N.N., Colhoun H.M., Vallance P. Cardiovascular risk factors as determinants of endothelium-dependent and endotheliumindependent vascular reactivity in the general population. J Am Coll Cardiol. 2001;38:1814-2.
    1. Davies M.J. The composition of coronary-artery plaques. N Engl J Med. 1997;336:1312–1314.
    1. Zhou Y.F., Wanishsawad C., Epstein S.E. Chlamydia pneumonia-induced transactivation of cytomegalovirus: potential synergy of infectious agents in the pathogenesis of atherosclerosis. J Am Coll Cardiol. 1999;33(suppl. A):260A.
    1. Conti C.R. Vascular events responsible for thrombotic occlusion of a blood vessel. Clin Cardiol. 1993;16:761–762.
    1. Lundman P., Eriksson M., Schenck-Gustafsson K. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation. 1997;96:3266–3268.
    1. Kawano H., Motoyama T., Hirai N. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146–154.
    1. Gwini S.M., Coupland C.A., Siriwardena A.N. The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. Vaccine. 2011;29(6):1145–1149.
    1. Naghavi M., Barlas Z., Siadaty S. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102:3039–3045.
    1. Meyers D., Beahm D., Jurisich P. Influenza and pneumococcal vaccinations fail to prevent myocardial infarction. Heart Drug. 2004;4:96–100.
    1. Lavellee P., Perchaud V., Gautier-Bertrand M. Association between influenza vaccination and reduced risk of brain infarction. Stroke. 2002;33:513–518.
    1. Siscovick D., Raghunathan T., Lin D. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol. 2000;152:674–677.
    1. Siriwardena A., Gwini S., Coupland C. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ. 2010;182:1617–1623.
    1. Heffelfinger J., Heckbert S., Psaty B. Influenza vaccination and risk of incident myocardial infarction. Hum Vaccin. 2006;2:161–166.
    1. Nichol K., Nordin J., Mullooly J. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322–1332.
    1. Jackson L., Yu O., Heckbert S. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol. 2002;156:634–640.
    1. Armstrong B., Mangtani P., Fletcher A. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ. 2004;329:660–663.
    1. Wang C., Wang S., Lai C. Impact of influenza vaccination on major cause-specific mortality. Vaccine. 2007;25:1196–1203.
    1. Johnstone J., Loeb M., Teo K.K. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation. 2012;126(3):278–286.
    1. Kwong J.C., Schwartz K.L., Campitelli M.A. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(26):2540–2541.
    1. Barnes M., Heywood A.E., Mahimbo A. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101(21):1738–1747.
    1. Warren-Gash C., Blackburn R., Whitaker H. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51(3)
    1. Keller T., Weeds V., van Dongen C. Influenza vaccines for preventing coronary heart disease. Cochrane Database Syst Rev. 2008;3
    1. Warren-Gash C., Smeeth L., Hayward A.C. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9:602–610.
    1. Udell J.A., Zawi R., Bhatt D.L. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310:1711–1720.
    1. Clar C., Oseni Z., Flowers N. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015;5
    1. Dokainish H., Teo K., Zhu J. Heart failure in low- and middle-income countries: background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF) Am Heart J. 2015;170(4):627-634.e1.
    1. Fukuta H., Goto T., Wakami K. The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2018
    1. ONTARGET Investigators, Yusuf S., Teo K.K. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
    1. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S., Teo K. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–1183.
    1. Yusuf S., Pfeffer M.A., Swedberg K. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–781.
    1. Yu H., Alonso W.J., Feng L. Characterization of regional influenza seasonality patterns in China and implications for vaccination strategies: spatio-temporal modeling of surveillance data. PLoS Med. 2013;10(11)
    1. Chadha M.S., Potdar V.A., Saha S. Dynamics of influenza seasonality at sub-regional levels in india and implications for vaccination timing. PLoS ONE. 2015;10(5)
    1. Osterholm M.T., Kelley N.S., Sommer A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44.
    1. Belongia E.A., Simpson M.D., King J.P. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–951.
    1. Demicheli V., Jefferson T., Di Pietrantonj C. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2018;2
    1. Vardeny O., Udell J.A., Joseph J. High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. Am Heart J. 2018;202:97–103.
    1. Fröbert O., Götberg M., Angerås O. Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. Am Heart J. 2017;189:94–102.
    1. GBD 2017 Influenza Collaborators Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019;7(1):69–89.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner